Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
28 results
- D3.03 - Trend analysis of the occurrence of allergic diseases in Polish children over the past 30 years
- D3.05 - Predictive Value of Bronchodilator Reversibility and FeNO in Assessing Positive Outcomes of Bronchial Provocation Tests in Asthma Patients
- D3.02 - Benefits of non-invasive methods in the diagnosis of occupational asthma: example of asthma due to ammonium persulphate in a hairdresser
- D3.07 - Allergic Asthma in Children: The Hidden Role of Cockroaches
- D3.08 - Cross-disciplinary working in adult food allergy: experience from the UK
- D3.10 - Systemic characteristic of 15-LOX and 5-LOX oxo-metabolites in older patients with aspirin exacerbated respiratory disease
- D3.11 - Bird-Egg Syndrome and Beyond: Exploring Allergies to Egg Yolk and Seeds from Bird Feed Components
- D3.12 - A case of Pneumothorax as first manifestation of asthma
- D3.13 - Real-life experience with tezepelumab in severe allergic asthma
- D3.14 - Validation of an environmental exposure chamber for the diagnosis of olive tree pollen allergy
- D3.15 - Mislabeling of Anaphylaxis in the Emergency Department: A Retrospective Study at King Abdulaziz University Hospital, Jeddah
D3.16 - Recommendations to travelers with pollen allergy, main pollens identified in aerobiological stations from Perú and Spain
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
D3.416 - Hereditary Alpha-Tryptasemia: A Case Series
D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download